What question did this study set out to answer?

To evaluate the outcomes of different immunosuppression induction strategies in simultaneous heart-kidney transplant (SHKT) recipients.

April 10, 2026

Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

Puntos clave

To evaluate the outcomes of different immunosuppression induction strategies in simultaneous heart-kidney transplant (SHKT) recipients.
Data analysis from the United Network for Organ Sharing (UNOS) database.
Comparison of 1-year outcomes across various induction strategies.
Specific focus on patients receiving basiliximab.
1-year outcomes are similar across different induction strategies in SHKT recipients.
Basiliximab is effective for standard-risk SHKT recipients.

Resumen

Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.

Me gusta

Guardar